Clicky

Mesoblast Limited(MESO)

Description: Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.


Keywords: Biotechnology Life Sciences Stem Cell Rheumatoid Arthritis Cardiovascular Disease Pharmaceutical Industries Bone Hematology Therapeutic Products Transplantation Heart Failure Vascular Disease Spine Proprietary Technology Bone Marrow Skeletal Disorders Diabetic Nephropathy Adult Stem Cell Back Pain Regenerative Biomedicine Congestive Heart Failure Host Disease Graft Versus Host Disease Spinal Fusion Ischemia Mesoblast Cardiac Diseases Cell Product Inflammatory Conditions Teva Pharmaceutical Industries Degenerative Disc Disease Musculoskeletal Disorders Adult Stem Cell Products Bone Marrow Transplantation

Home Page: www.mesoblast.com

MESO Technical Analysis

55 Collins Street
Melbourne, VIC 3000
Australia
Phone: 61 3 9639 6036


Officers

Name Title
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec.
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S. Head of Manufacturing
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 833.3333
Trailing PE: 0
Price-to-Book MRQ: 0.9299
Price-to-Sales TTM: 56.7856
IPO Date: 2015-11-13
Fiscal Year End: June
Full Time Employees: 77
Back to stocks